KARBAPENEMLERE DİRENÇLİ GRAM- NEGATİF BASİL ...

KAYNAKLAR
1. Kohler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities
against Pseudomonas aeruginosa: respective contributions of OprD and efflux
systems. Antimicrob Agents Chemother 1999;43:424-7.
2. Pai H, Kim JW, Kim J, et al. Carbapenem resistance mechanisms in Pseudomonas
aeruginosa clinical isolates. Antimicrob Agents Chemother 2001;45:480-4.
3. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin
Microbiol Infect 2002;8:321-33.
4. Fritshe TR, Sader HS, Toleman MA, Walsh TR, Jones RN. Emerging metallo-beta-
lactamase-mediated resistances: A summary report from the worldwide SENTRY
antimicrobial surveillance program. Clin Infect Dis 2005;41:S276-8.
5. Essack SY. The development of beta-lactam antibiotics in response to the evolution
of beta-lactamases. Pharmaceutical Research 2001;18:1391-9.
6. Gür D. Hastane infeksiyonlarında önem kazanan gram-negatif bakterilerde
antibiyotiklere direnç mekanizmaları. Hastane İnfeksiyonları Dergisi 1997;1:38-45.
7. Opal SM, Medeiros AA. Molecular mechanisms of antibiotic resistance in bacteria.
In: Mandell GL, Bennett JE, Dolin R (eds). Principles and Practice of Infectious
Diseases. Sixth edition, Pennsylvania: Elsevier Churchill Livingstone Inc,
2005:253-70.
8. Chambers HF. Penicillins. In: Mandell GL, Bennett JE, Dolin R (eds). Principles
and Practice of Infectious Diseases. Sixth edition, Pennsylvania: Elsevier Churchill
Livingstone Inc, 2005:281-93.
9. Andes DR, Craig WA. Cephalosporins. In: Mandell GL, Bennett JE, Dolin R (eds).
Principles and Practice of Infectious Diseases. Sixth edition, Pennsylvania: Elsevier
Churchill Livingstone Inc, 2005:294-311.
10. Harold C, Neu M D. Relation of structural properties of beta-lactam antibiotics to
antibacterial activity. Am J Med 1985;(Suppl 2A):2-13.
11. Livermore DM, Woodford N. Carbapenemases: a problem in waiting?. Curr Opin
Microbiol 2000;3:489-95.
49